Product Description

CTX-1302 utilizes a breakthrough multi-core formulation of dextroamphetamine, a compound approved by the FDA for the treatment of ADHD. CTX-1302 combines layers of immediate release and sustained release active pharmaceutical ingredient in a single pill intended to deliver pulses of active ingredient when patients need it, delivering a rapid onset and lasting the entire active day while minimizing the afternoon crash and impact on sleep and appetite.

 

Clinical Trials

After a planned Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2018, Cingulate intends to implement the full clinical plan for CTX-1302 in 2018.